Aptose Biosciences (NASDAQ:APTO) (TSE:APS) was downgraded by equities research analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research note issued on Friday.

Other research analysts have also recently issued research reports about the company. Zacks Investment Research upgraded Aptose Biosciences from a “hold” rating to a “buy” rating and set a $2.00 price target for the company in a research note on Friday, November 17th. Canaccord Genuity set a $7.00 price target on Aptose Biosciences and gave the stock a “buy” rating in a research note on Wednesday, November 15th. HC Wainwright set a $4.00 price target on Aptose Biosciences and gave the stock a “buy” rating in a research note on Wednesday, November 15th. Finally, Roth Capital restated a “buy” rating and issued a $5.00 price target on shares of Aptose Biosciences in a research note on Monday, October 23rd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $4.50.

Aptose Biosciences (NASDAQ:APTO) traded down $0.02 during mid-day trading on Friday, hitting $2.01. The stock had a trading volume of 312,144 shares, compared to its average volume of 393,563. Aptose Biosciences has a 52-week low of $0.78 and a 52-week high of $2.30.

ILLEGAL ACTIVITY WARNING: “Aptose Biosciences (APTO) Stock Rating Lowered by ValuEngine” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another website, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/12/01/aptose-biosciences-apto-stock-rating-lowered-by-valuengine.html.

About Aptose Biosciences

Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.

Receive News & Stock Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related stocks with our FREE daily email newsletter.